Completed PHASE1 INTERVENTIONAL 5-arm NCT05051566

A Multiple Dose Study of LY3502970 in Healthy Participants

A Multiple Dose Study in Healthy Participants to Investigate the Safety, Tolerability, and Pharmacokinetics of LY3502970

Sponsor: Eli Lilly and Company

Conditions Healthy

Interventions Esomeprazole LY3502970

Updated 7 times since 2021 Last updated: Apr 25, 2022 Started: Sep 16, 2021 Primary completion: Apr 4, 2022 Completion: Apr 4, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Healthy, this trial is completed. The trial is conducted by Eli Lilly and Company and has accumulated 7 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
May 2022 — Jul 2024 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
Apr 2022 — May 2022 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
Jan 2022 — Apr 2022 [monthly]

Recruiting PHASE1

▶ Show 2 earlier versions

Nov 2021 — Jan 2022 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Oct 2021 — Nov 2021 [monthly]

Not Yet Recruiting PHASE1

First recorded

Sep 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eli Lilly and Company
Quotient Sciences

Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nottingham, United Kingdom